GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: Identification of a population at risk of leukemia

Blood

Volumn 122, Issue 24, 2013, Pages 3908-3917

  Roberts, Irene ^a   Alford, Kate ^b   Hall, Georgina ^c   Juban, Gaetan ^b   Richmond, Helen ^a   Norton, Alice ^b   Vallance, Grant ^b,c   Perkins, Kelly ^b   Marchi, Emanuele ^b   McGowan, Simon ^b   Roy, Anindita ^a   Cowan, Gillian ^a   Anthony, Mark ^c   Gupta, Amit ^c   Ho, John ^d   Uthaya, Sabita ^e   Curley, Anna ^f   Rasiah, Shree Vishna ^g   Watts, Timothy ^h   Nicholl, Richard ⁱ   Bedford Russell, Alison ^j   Blumberg, Raoul ^k   Thomas, Angela ^l   Gibson, Brenda ^m   Halsey, Chris ^m   Lee, Pek Wan ⁿ   Godambe, Sunit ^o   Sweeney, Connor ^b   Bhatnagar, Neha ^a   Goriely, Anne ^b   Campbell, Peter ^p   Vyas, Paresh ^b,c   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ EALING HOSPITAL NHS TRUST   (United Kingdom)

^j UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^k WHITTINGTON HOSPITAL   (United Kingdom)

^l ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^m ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

ⁿ ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^o ST MARY S HOSPITAL   (United Kingdom)

^p WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA POLYMERASE; TRANSCRIPTION FACTOR GATA 1;

ACUTE MYELOID LEUKEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD SMEAR; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DOWN SYNDROME; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KARYOTYPING; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MOLECULAR CLONING; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NEWBORN; NEXT GENERATION SEQUENCING; PRELEUKEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SANGER SEQUENCING; TRANSIENT ABNORMAL MYELOPOIESIS; ACUTE DISEASE; BLOOD; CELL CLONE; CELL TRANSFORMATION; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOID; METABOLISM; MUTATION; MYELOPOIESIS; NEWBORN SCREENING; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR EMBOLISM;

ACUTE DISEASE; CELL TRANSFORMATION, NEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONE CELLS; DNA MUTATIONAL ANALYSIS; DOWN SYNDROME; GATA1 TRANSCRIPTION FACTOR; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT, NEWBORN; LEUKEMIA, MYELOID; MUTATION; MYELOPOIESIS; NEONATAL SCREENING; NEOPLASTIC CELLS, CIRCULATING; PRELEUKEMIA; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84891061196     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-515148     Document Type: Article

References (40)

1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355(9199): 165-169.
2. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group Studies 2861 and 2891. Blood. 1998;91(2):608-615.
3. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103(7):2480-2489.
4. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101(11):4301-4304.
5. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102(3):981-986.
6. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1):148-152.
7. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102(8):2960-2968.
8. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down’s syndrome with transient myeloid disorder. Lancet. 2003;361(9369):1617-1620.
9. Taub JW, Mundschau G, Ge Y, et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 2004;104(5): 1588-1589.
10. Zipursky A. Transient leukaemia — a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003;120(6):930-938.
11. Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111(6):2991-2998.
12. Massey GV, Zipursky A, Chang MN, et al; Children’s Oncology Group (COG). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107(12):4606-4613.
13. Muramatsu H, Kato K, Watanabe N, et al. Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br J Haematol. 2008;142(4):610-615.
14. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118(26):6752-6759, quiz 6996.
15. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
16. Henry E, Walker D, Wiedmeier SE, Christensen RD. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A. 2007;143(1):42-50.
17. Pine SR, Guo Q, Yin C, et al. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007; 110(6):2128-2131.
18. Cantù Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I; European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol. 2005;84(7): 429-433.
19. Noris P, Pecci A, Di Bari F, et al. Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica. 2004;89(10):1219-1225.
20. Sarkar S, Rosenkrantz TS. Neonatal polycythemia and hyperviscosity. Semin Fetal Neonatal Med. 2008;13(4):248-255.
21. Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonate. Blood Rev. 2008;22(4):173-186.
22. Stanworth SJ, Clarke P, Watts T, et al; Platelets and Neonatal Transfusion Study Group. Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics. 2009;124(5):e826-e834.
23. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2): 277-282.
24. Alford KA, Reinhardt K, Garnett C, et al; International Myeloid Leukemia-Down Syndrome Study Group. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011; 118(8):2222-2238.
25. Li H, Handsaker B, Wysoker A, et al; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
26. Rankin J, Tennant PW, Bythell M, Pearce MS. Predictors of survival in children born with Down syndrome: a registry-based study. Pediatrics. 2012;129(6):e1373-e1381.
27. Chakravorty S, Roberts I. How I manage neonatal thrombocytopenia. Br J Haematol. 2012;156(2): 155-162.
28. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005;217(3):126-134.
29. Tunstall-Pedoe O, Roy A, Karadimitris A, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood. 2008;112(12):4507-4511.
30. Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112(12):4503-4506.
31. Roy A, Cowan G, Mead AJ, et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci USA. 2012;109(43):17579-17584.
32. Maclean GA, Menne TF, Guo G, Sanchez DJ, Park IH, Daley GQ, Orkin SH. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA. 2012; 109(43):17567-17572.
33. Chou ST, Byrska-Bishop M, Tober JM, et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA. 2012;109(43):17573-17578.
34. Birger Y, Goldberg L, Chlon TM, et al. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome’s transient myeloproliferative disorder. Blood. 2013;122(6): 988-998.
35. Amiel A, Goldzak G, Gaber E, Fejgin MD. Molecular cytogenetic characteristics of Down syndrome newborns. J Hum Genet. 2006;51(6):541-547.
36. Nižetić D, Groet J. Tumorigenesis in Down’s syndrome: big lessons from a small chromosome. Nat Rev Cancer. 2012;12(10):721-732.
37. Nik-Zainal S, Alexandrov LB, Wedge DC, et al; Breast Cancer Working Group of the International Cancer Genome Consortium. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149(5):979-993.
38. Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica. 2013;98(4):568-575.
39. Bull MJ; Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011;128(2):393-406.
40. Hasle H, Abrahamsson J, Arola M, et al. Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia. 2008;22(7):1428-1430.